Ahead of its annual general meeting in May 2027, Sobi's nomination committee has announced its proposed new chair. The ...
Eli Lilly is discontinuing development of its Alzheimer’s drug candidate mevidalen. The decision follows a phase II trial ...
AstraZeneca beat market expectations in the third quarter. At the same time, the company announced a cost-cutting programme ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results